Scienture Holdings, Inc. has entered into a securities purchase agreement with institutional investors to purchase 3,225,000 shares of common stock at $1.20 per share.
The gross proceeds from the offering are expected to be approximately $3.9 million before deducting fees and expenses.
The offering is expected to close on August 15, 2025, subject to customary closing conditions.
Offering Details
3,225,000 shares of common stock at $1.20 per share
Gross Proceeds
Approximately $3.9 million expected before deductions
Closing Date
Expected to close on August 15, 2025
- The offering strengthens Scienture's financial position by raising approximately $3.9 million.
- It reflects investor confidence in the company's growth prospects and planned pharmaceutical operations.
This registered direct offering marks a significant milestone for Scienture Holdings, Inc. as it secures additional funding for its pharmaceutical activities.